Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer

NCT03370367 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT03370367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03370367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
May 15, 1989
Completion date
April 14, 2015
Enrollment
189 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage i-ii head and neck cancer